Back to News
Market Impact: 0.25
BioArctic collaborator Novartis terminates agreement
Source: PR Newswire
M&A & RestructuringCompany Fundamentals
BioArctic said Novartis Pharma AG decided to terminate the Option, Collaboration and License Agreement the companies entered into in August 2025 to explore a potential new opportunity. The notice provides no financial terms, reason for termination, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
BIOA.B-0.70
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash